<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533613491982</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533613491982</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Gastroparesis</article-title>
<subtitle>From Concepts to Management</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Bouras</surname><given-names>Ernest P.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0884533613491982">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Vazquez Roque</surname><given-names>Maria I.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0884533613491982">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Aranda-Michel</surname><given-names>Jaime</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0884533613491982">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0884533613491982"><label>1</label>Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida</aff>
<author-notes>
<corresp id="corresp1-0884533613491982">Ernest P. Bouras, MD, Division of Gastroenterology &amp; Hepatology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Email: <email>bouras.ernest@mayo.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>4</issue>
<fpage>437</fpage>
<lpage>447</lpage>
<permissions>
<copyright-statement>© 2013 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p>While the symptoms of gastroparesis are common, an accurate diagnosis is based on a combination of those symptoms with a documented delay in gastric emptying. Typical symptoms include nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal discomfort. Patients with gastroparesis face many diagnostic and therapeutic challenges. The most common origins of gastroparesis are idiopathic causes and diabetes mellitus. The increased use of certain medications in medicine today, including opiates and drugs with anticholinergic properties, can alter gastrointestinal functions and mimic symptoms of gastroparesis. Accordingly, alternative explanations for symptoms and altered gastrointestinal function need to be considered. Numerous clinical sequelae, including weight loss and severe protein-calorie malnutrition, may be seen in advanced stages of gastroparesis. This article provides an overview of gut sensorimotor function to help the reader better understand the clinical presentation of patients with dyspepsia and those who may have accompanying delayed gastric emptying that meets criteria for gastroparesis. Techniques available for diagnosing motor dysfunction and the principles of gastroparesis management are reviewed. Nutrition recommendations and a review of pharmacologic agents, nonpharmacologic techniques, and novel treatment modalities are provided.</p>
</abstract>
<kwd-group>
<kwd>gastroparesis</kwd>
<kwd>gastrointestinal motility</kwd>
<kwd>nutritional support</kwd>
<kwd>enteral nutrition</kwd>
<kwd>gastric emptying</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Gastroparesis is a disorder of delayed gastric emptying that has received increased attention over the last several years. This increased clinical awareness has been complemented by an increase in the technology used for both diagnosis and management of the disorder. However, when it comes to treatment, gastric motility disorders remain a challenge for patients and physicians alike. To gain a better understanding of the patients presenting with dyspepsia and delayed gastric emptying, it is essential to understand gastrointestinal motor function and concepts involving visceral sensation.</p>
<p>The objectives of this review article are (a) to provide an overview of gastric motor and sensory function to help the reader better understand the clinical presentation of patients with dyspepsia and those who may have accompanying delayed gastric emptying, (b) to identify the criteria required for an accurate diagnosis of gastroparesis, (c) to describe the diagnostic tools used to assess gastric emptying, and (d) to highlight the current treatment strategies, with an emphasis on nutrition management.</p>
<sec id="section1-0884533613491982">
<title>Gut Motor and Sensory Function</title>
<p>Movement of food through the gastrointestinal tract is accomplished through a series of complex actions and interactions of the neuromuscular and endocrine components that constitute the gastrointestinal tract. The neuromuscular control of gastric motor functions is mediated by the enteric nervous system (ENS) and the parasympathetic (through the vagus nerve) and sympathetic nervous system interacting with the interstitial cells of Cajal (ICCs) and smooth muscle cells. The ENS is a group of ganglia organized in specific plexi that function independently, but it also integrates signals from the autonomic and central nervous system. Much of the gastric motor function is controlled by an innate cyclic electrical activity felt to originate from the greater curvature of the stomach, occurring at a frequency of 3 cycles per minute (CPM). The ICCs, which function as the pacemaker system that creates the basic electrical rhythm for gastric motility, are directly coupled to smooth muscle cells and result in their excitation when the 3 CPM activity reaches threshold amplitude. During the fasting period there is a unique motility pattern of highly regulated motor pattern in the stomach called the migrating motor complex (MMC). These periodic “housekeeping” contractions empty nondigestible solids from the stomach.</p>
<p>Abnormalities in this intricate network have been identified in various gastrointestinal disorders. During a meal, there is a vagally mediated gastric accommodation and receptive relaxation of the stomach that facilitates the ingestion of liquids or solids without inducing symptoms (<xref ref-type="fig" rid="fig1-0884533613491982">Figure 1</xref>). While the proximal stomach tends to serve as a reservoir, the distal stomach is responsible for triturating and mixing gastric contents, preparing them for delivery into the small bowel. Gastric emptying is a complex process that can be delayed by a variety of factors including meal macronutrient content, hormones, nerves, muscles, and the functional resistance of the duodenum. Further, meal content and medications (such as narcotics and anticholinergics) delay gastric motor functions.</p>
<fig id="fig1-0884533613491982" position="float">
<label>Figure 1.</label>
<caption>
<p>Gastric motor function. Gastric function can be divided into activity in the proximal stomach (receptive relaxation and fundic empting) and body/antrum (mixing, peristalsis, and emptying). In addition, a gastric pacemaker helps coordinate gastric motility. The pylorus provides resistance to emptying that aids mixing and relaxes to allow food to pass into the duodenum. Adapted with permission from John Wiley and Sons.<sup><xref ref-type="bibr" rid="bibr1-0884533613491982">1</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_0884533613491982-fig1.tif"/>
</fig>
<p>Visceral sensation is accomplished via both ascending and descending neurological pathways (<xref ref-type="fig" rid="fig2-0884533613491982">Figure 2</xref>). In addition to being influenced by the vagus nerve, which has a prominent role, afferent stimulation occurs via a 3-neuron chain, which leads to central processing of the input. The following sensation has both sensory-discriminative and affective-motivational components. Descending pathways have an impact via efferent action, which can modulate activity. Differences that may exist among individuals likely lead to differences in sensory appreciation, manifesting as gastrointestinal symptoms in many people.</p>
<fig id="fig2-0884533613491982" position="float">
<label>Figure 2.</label>
<caption>
<p>Gastric sensory function. Visceral sensation is accomplished via both ascending and descending neurological pathways. Ascending pathways travel through a 3-neuron chain with ultimate central processing, yielding sensation with sensory-discriminative and affective-motivational components. Descending pathways play an active role in modulating this activity.</p>
</caption>
<graphic xlink:href="10.1177_0884533613491982-fig2.tif"/>
</fig>
</sec>
<sec id="section2-0884533613491982">
<title>Making the Diagnosis of Gastroparesis</title>
<sec id="section3-0884533613491982">
<title>Presenting History and Symptoms</title>
<p>The diagnosis of gastroparesis must be based on a combination of symptoms and a documented delay in gastric emptying in the absence of mechanical obstruction or ulceration.<sup><xref ref-type="bibr" rid="bibr2-0884533613491982">2</xref></sup> An abnormal gastric emptying test without appropriate symptoms is not gastroparesis. Typical symptoms of gastroparesis include nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal discomfort. Timing and extent of symptoms are important, and patients with constant symptoms or immediate symptoms (even in response to small amounts of liquid or food) likely have a different explanation for their presentation. Chronic, constant, or severe abdominal pain, particularly if not meal-related, should lead one to consider alternate diagnoses. The presence of rumination syndrome (effortless regurgitation of recently ingested food unassociated with retching),<sup><xref ref-type="bibr" rid="bibr3-0884533613491982">3</xref></sup> eating disorders, and cyclic vomiting syndrome should be excluded.</p>
</sec>
<sec id="section4-0884533613491982">
<title>Causes</title>
<p>Diabetes mellitus, previous surgery, and idiopathic causes are the most common origins of gastroparesis.<sup><xref ref-type="bibr" rid="bibr4-0884533613491982">4</xref></sup> Of these, idiopathic causes appear to be the most common origin, but diabetes mellitus remains the most commonly recognized systemic disease associated with the disorder.<sup><xref ref-type="bibr" rid="bibr2-0884533613491982">2</xref></sup> However, the delay in gastric emptying may not always be the key in symptom generation, as patients may also suffer from a “sensory gastropathy.” Reports of gastroparesis in up to 40% of patients with diabetes<sup><xref ref-type="bibr" rid="bibr5-0884533613491982">5</xref><xref ref-type="bibr" rid="bibr6-0884533613491982"/><xref ref-type="bibr" rid="bibr7-0884533613491982"/><xref ref-type="bibr" rid="bibr8-0884533613491982"/>-<xref ref-type="bibr" rid="bibr9-0884533613491982">9</xref></sup> are likely secondary to a tertiary referral bias. In one report, the prevalence in patients with diabetes in the community was estimated to be 5% for type 1 diabetes and 1% in type 2 diabetes.<sup><xref ref-type="bibr" rid="bibr10-0884533613491982">10</xref></sup> The underlying pathophysiologic mechanism in diabetes mellitus is thought to be a neuropathic process, with components of autonomic dysfunction and an enteric neuropathy with loss of the ICCs (the pacemaker cells of the gut) in patients with long-standing insulin-dependent diabetes mellitus.<sup><xref ref-type="bibr" rid="bibr11-0884533613491982">11</xref><xref ref-type="bibr" rid="bibr12-0884533613491982"/><xref ref-type="bibr" rid="bibr13-0884533613491982"/>-<xref ref-type="bibr" rid="bibr14-0884533613491982">14</xref></sup></p>
<p>Idiopathic gastroparesis is most commonly seen in women, typically young or middle-aged.<sup><xref ref-type="bibr" rid="bibr15-0884533613491982">15</xref>,<xref ref-type="bibr" rid="bibr16-0884533613491982">16</xref></sup> Gastroparesis appears to have developed after a viral infection in a subset of these patients, suggesting a postviral syndrome.<sup><xref ref-type="bibr" rid="bibr17-0884533613491982">17</xref>,<xref ref-type="bibr" rid="bibr18-0884533613491982">18</xref></sup> In most patients, symptoms improve over the course of a year, although a minority of patients may have a slower resolution of symptoms.<sup><xref ref-type="bibr" rid="bibr19-0884533613491982">19</xref></sup> Iatrogenic gastroparesis may be surgical (eg, intentional or unintentional vagal nerve disruption) or pharmacologic (eg, narcotics, anticholinergic agents, certain medications used to treat diabetes, cyclosporine). A thorough review of a patient’s medication history is essential for patients presenting with dyspepsia, as the impact of medications on symptoms cannot be overstated. Other causes of gastroparesis include neuropathic disorders (eg, autonomic dysfunction, Parkinsonism, paraneoplastic disorders), connective tissue diseases (eg, scleroderma), and infiltrating diseases (eg, amyloidosis).</p>
</sec>
<sec id="section5-0884533613491982">
<title>Diagnostic Tools</title>
<p>Scintigraphic gastric emptying of a solid meal is the gold standard for evaluation of gastroparesis. The most well-established test uses a scrambled egg that is labeled with a radionuclide (eg, 99m technetium) that binds to protein in the test meal. Scintigraphic images are obtained over a specified period of time, and the rate of gastric emptying can be determined. The most reliable information is obtained during a 4-hour study compared with studies of shorter duration. The significance of a delay in emptying over a 1- to 2-hour study that normalizes over time is uncertain. Although it is possible to measure liquid gastric emptying, the clinical significance has not been assessed.</p>
<p>This nuclear medicine technology is widely available and relatively inexpensive, and the tests are easy to perform once standardized values have been established in healthy individuals for the test used by a specific nuclear medicine facility. Meals and techniques have been standardized and tested in a multicenter fashion and have been advocated by the Society of Nuclear Medicine and the American Neurogastroenterology and Motility Society.<sup><xref ref-type="bibr" rid="bibr20-0884533613491982">20</xref></sup> Patients need to stop medications that may affect gastric emptying at an appropriate time prior to testing. As hyperglycemia leads to abnormal gastric emptying, it has been recommended that patients with diabetes have their blood glucose level measured before starting a gastric emptying test documenting a level &lt;275 mg/dL.</p>
<p>Novel techniques that have certain advantages of portability and no radiation exposure have been developed. A wireless motility capsule can assess gastric emptying by measuring pH, with a rapid increase in pH suggesting passage of the capsule out of the stomach. Investigators have shown the overall correlation between gastric emptying times via scintigraphy and the wireless motility capsule to be 0.73, with the 5-hour gastric residence time serving as the best marker to differentiate people with normal or delayed gastric emptying compared with simultaneous scintigraphy.<sup><xref ref-type="bibr" rid="bibr21-0884533613491982">21</xref></sup> Although provocative, <sup><xref ref-type="bibr" rid="bibr13-0884533613491982">13</xref></sup>C breath testing using octanoate or spirulina incorporated into a solid meal<sup><xref ref-type="bibr" rid="bibr22-0884533613491982">22</xref>,<xref ref-type="bibr" rid="bibr23-0884533613491982">23</xref></sup> requires further validation before it can be considered as an alternative to scintigraphy. Magnetic resonance imaging is expensive, time-insensitive, and not widely available. Electrogastrography does not measure actual emptying, it requires expertise, and its clinical role remains uncertain. The use of these alternative methods of assessing gastric function is typically isolated to research centers.</p>
<p>Gastrointestinal manometry can be performed using water-perfused or solid-state systems.<sup><xref ref-type="bibr" rid="bibr24-0884533613491982">24</xref></sup> This invasive study involves placement of a specialized manometry catheter in the upper gastrointestinal tract where motility patterns of the stomach and small bowel can be observed in the laboratory for 6–8 hours or as part of an ambulatory study for longer periods of time. Gastrointestinal manometry is most useful in select patients who have abnormalities of gastric emptying with no obvious explanation. Although gastrointestinal manometry is not intended to provide a specific diagnosis, these studies (which are performed at a limited number of motility centers) can reveal characteristic patterns that suggest an underlying neuropathy, myopathy, or intestinal mechanical obstruction.<sup><xref ref-type="bibr" rid="bibr25-0884533613491982">25</xref></sup></p>
<p>Tools such as a gastric barostat,<sup><xref ref-type="bibr" rid="bibr26-0884533613491982">26</xref>,<xref ref-type="bibr" rid="bibr27-0884533613491982">27</xref></sup> single photon emission computed tomography (SPECT),<sup><xref ref-type="bibr" rid="bibr28-0884533613491982">28</xref></sup> and satiety testing with a nutrient drink test<sup><xref ref-type="bibr" rid="bibr29-0884533613491982">29</xref>,<xref ref-type="bibr" rid="bibr30-0884533613491982">30</xref></sup> have been used to explore other gastric functions (such as sensation and gastric accommodation) in an attempt to better understand symptom generation. These tests are primarily offered in a research setting at a limited number of motility centers.</p>
</sec>
<sec id="section6-0884533613491982">
<title>Other Considerations</title>
<p>In individuals receiving medications known to cause delays in gastric emptying, including narcotics, anticholinergic agents, and glucagon-like peptide-1 (GLP-1) as well as amylin analogs in patients with diabetes mellitus,<sup><xref ref-type="bibr" rid="bibr31-0884533613491982">31</xref>,<xref ref-type="bibr" rid="bibr32-0884533613491982">32</xref></sup> it is difficult to make a diagnosis of gastroparesis given the impact of these medications on gastric sensorimotor function. The increased use of many of these drugs has led to the misdiagnosis of gastroparesis in many patients. It is important to inquire about these medications during a careful history taking and prior to scintigraphic gastric emptying, since these need to be stopped for an appropriate period of time to establish an accurate diagnosis. Cannabinoids are increasingly used for symptoms of nausea and may cause a syndrome of frequent vomiting called cannabis hyperemesis syndrome. With this particular syndrome, patients should be advised to stop using these agents.</p>
<p>Delayed gastric emptying has been described in certain syndromes, such as functional dyspepsia (FD), which is a syndrome characterized by dyspeptic symptoms with no evidence of structural disease.<sup><xref ref-type="bibr" rid="bibr33-0884533613491982">33</xref></sup> Delayed gastric emptying has been identified in up to one-third of patients with FD.<sup><xref ref-type="bibr" rid="bibr34-0884533613491982">34</xref>,<xref ref-type="bibr" rid="bibr35-0884533613491982">35</xref></sup> Many of these patients also have abnormalities in gastric sensation and accommodation. There is controversy on how to define or classify dyspeptic patients and whether the delayed gastric emptying is clinically significant. Ongoing research is needed in this area to help better define patient populations with regard to their gastrointestinal motor and sensory function, with the goal of identifying modifiable physiological factors that would affect symptom generation.</p>
<p>Symptoms are often attributed to altered passage of food through the gut. However, there is poor correlation between symptoms and specific abnormalities seen on gastric emptying studies, emphasizing that treatment cannot be based on abnormalities of radionuclide studies alone. This highlights the importance of looking beyond alterations in motility, considering potential abnormalities of visceral sensation.</p>
</sec>
</sec>
<sec id="section7-0884533613491982">
<title>Management of Gastroparesis</title>
<p>Once gastroparesis has been properly diagnosed, several key management concepts emerge. The cause of the motility disorder (eg, idiopathic, diabetes, drugs, etc) should be determined. Patients should be screened for diabetes mellitus and thyroid dysfunction. Clinicians must look for a prodrome that may suggest a viral illness, as most patients with this condition of postviral gastroparesis and visceral hypersensitivity improve over time.</p>
<p>Complications of gastroparesis include fluid and electrolyte abnormalities, inadequate nutrition intake resulting in weight loss, difficult glycemic control (which exacerbates gastric dysmotility), gastroesophageal reflux, aspiration, and bezoar formation. Protein-calorie malnutrition is an underappreciated problem that deserves aggressive management.</p>
<p>General treatment principles for gastroparesis include (a) maintaining or restoring hydration and nutrition status, (b) optimizing glycemic control in patients with diabetes, (c) attempting to control symptoms, and (d) managing complications. <xref ref-type="fig" rid="fig3-0884533613491982">Figure 3</xref> provides an overview to the stepwise approach and management of patients with gastroparesis. Specific details are outlined below:</p>
<fig id="fig3-0884533613491982" position="float">
<label>Figure 3.</label>
<caption>
<p>Stepwise approach to gastroparesis.</p>
</caption>
<graphic xlink:href="10.1177_0884533613491982-fig3.tif"/>
</fig>
<sec id="section8-0884533613491982">
<title>Nutrition Assessment</title>
<p>A nutrition assessment should be performed in all patients with gastroparesis and should include changes in weight over time, fluid retention (peripheral edema), ongoing symptoms, associated diseases such as diabetes mellitus, and medication use. Evaluation by a well-trained dietitian and physician is essential. We favor the use of the Subjective Global Assessment (SGA) in these patients as it has a high degree of specificity in detecting malnutrition. Screening blood tests for malnutrition should include complete blood count (CBC) with differential, coagulation factors (international normalized ratio), and renal and liver profile. In patients with evidence of nutrition depletion, further mineral and vitamin screening should be conducted, including vitamin D (25-OH vitamin D), vitamin B<sub>12</sub>, folic acid, serum iron, total iron binding capacity (TIBC), percentage of iron saturation, and zinc levels.<sup><xref ref-type="bibr" rid="bibr36-0884533613491982">36</xref></sup> Accurate assessment of caloric intake is important, especially in patients with evidence of malnutrition. Prospective calorie counts should be performed in all patients, and proper caloric assessment is important to more accurately individualize nutrition support in these patients.</p>
<p>Assessment of energy expenditure (EE) should also be estimated to establish a patient’s caloric requirement. Different ways to calculate EE include (a) the Harris-Benedict equation, (b) multiplying the patient’s current body weight (in kilograms) by 25–30 kcal, and (c) indirect calorimetry (IC). The latter method is considered the gold standard for measuring EE; however, IC machines are not readily available in most institutions. In general, protein requirements of patients are 1.2–1.5 g/kg per day. Daily free water needs may be calculated as 1 mL/kcal or 30 mL per kilogram of actual body weight. These general recommendations should to be tailored to each individual’s specific presentation and needs.</p>
</sec>
<sec id="section9-0884533613491982">
<title>Diet</title>
<p>The majority of patients with gastroparesis can be managed with dietary modifications. Specific recommendations are based on an understanding of gastric physiological characteristics. Liquids empty more readily than solids, with small meal sizes of a low-fat content being the easiest to digest. A low-fiber diet is also easier to empty, and it decreases the risk of bezoar formation. Although high-osmolality solutions delay gastric emptying, it is unclear whether this is clinically relevant.</p>
<p>Small, frequent, and low-volume meals (4–6 per day) are also advantageous to minimize symptoms of postprandial fullness, nausea, and vomiting. Patients should be instructed to chew the food well into small particles to aid in the gastric emptying process. High-calorie liquids in small volumes can deliver energy and nutrients without significantly exacerbating symptoms.<sup><xref ref-type="bibr" rid="bibr37-0884533613491982">37</xref></sup> Patients should avoid carbonated drinks and other gaseous solutions, as these may exacerbate symptoms such as gastric distension and gastroesophageal reflux.<sup><xref ref-type="bibr" rid="bibr38-0884533613491982">38</xref></sup> Close follow-up with a dietitian should be organized to assess prospective caloric intake, nutrition status, and modification of nutrition supplements. In patients with diabetes, specialized nutrition supplements, including those with low glucose content, can be considered.</p>
<p>Electrolyte abnormalities can result from recurrent vomiting, and postoperative states can predispose patients to mineral and vitamin deficiencies.<sup><xref ref-type="bibr" rid="bibr39-0884533613491982">39</xref></sup> Nutrition intervention should focus on restoring hydration and maintaining calories and protein balance while replacing electrolyte, vitamin, and mineral deficiencies. These deficiencies may be mild or severe depending on the degree and chronicity of the gastroparesis. Patients should attempt to drink at least 1–1.5 L of fluid per day to avoid dehydration. Daily use of a multivitamin is recommended as well as additional supplements when vitamin or mineral deficiencies are identified.</p>
</sec>
<sec id="section10-0884533613491982">
<title>Prokinetic Therapy</title>
<sec id="section11-0884533613491982">
<title>Metoclopramide</title>
<p>Metoclopramide mediates its prokinetic actions as a peripheral dopamine D<sub>2</sub>-receptor antagonist that augments acetylcholine release in the myenteric plexus, thereby enhancing antroduodenal coordination, pyloric function, and jejunal peristalsis. Metoclopramide also has central antiemetic effects via direct action on the chemoreceptor trigger zone and the intracerebral vomiting center, which likely plays a significant role in symptom improvement. It is the only medication approved by the U.S. Food and Drug Association (FDA) to treat gastroparesis. Recommended use is for no longer than 12 weeks, unless patients experience a therapeutic benefit that outweighs the potential risks of the medication (<xref ref-type="table" rid="table1-0884533613491982">Table 1</xref>).<sup><xref ref-type="bibr" rid="bibr40-0884533613491982">40</xref></sup></p>
<table-wrap id="table1-0884533613491982" position="float">
<label>Table 1.</label>
<caption>
<p>Medications for Gastroparesis.</p>
</caption>
<graphic alternate-form-of="table1-0884533613491982" xlink:href="10.1177_0884533613491982-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Medication</th>
<th align="center">Mechanism of Action</th>
<th align="center">Oral Dose</th>
<th align="center">Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metoclopramide</td>
<td>Dopamine antagonist</td>
<td>5–20 mg, 4 times per day</td>
<td>Prokinetic and antiemetic properties<break/>Side effects in &gt;20%, start at low dose</td>
</tr>
<tr>
<td>Domperidone</td>
<td>Dopamine antagonist</td>
<td>10–20 mg, 4 times per day</td>
<td>Not available for prescription use in the U.S.<break/>Better side effect profile than metoclopramide</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>Motilin agonist</td>
<td>125–250 mg, 2–4 times per day</td>
<td>Strong prokinetic agent, short-term use favored<break/>Long-term use limited secondary to tachyphylaxis</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The efficacy of metoclopramide has been demonstrated in short-term clinical trials showing improvement of symptoms and acceleration of gastric emptying.<sup><xref ref-type="bibr" rid="bibr41-0884533613491982">41</xref><xref ref-type="bibr" rid="bibr42-0884533613491982"/><xref ref-type="bibr" rid="bibr43-0884533613491982"/>-<xref ref-type="bibr" rid="bibr44-0884533613491982">44</xref></sup> The drug is available as an oral dissolution tablet, as an oral tablet, as a liquid, and in a parenteral formulation (intravenous and subcutaneous). In hospitalized patients with intractable nausea and vomiting, the intravenous route may be useful at a dose of 5–10 mg every 3–6 hours. The oral dose is 5–20 mg, 4 times a day, 30 minutes before meals and at bedtime. The liquid formulation is favored in patients with significant gastroparesis because stomach emptying and drug absorption are more reliable for liquids. Beginning at a low dose (eg, 5 mg, 4 times per day) and advancing the dose only as needed are recommended.</p>
<p>The side effects of metoclopramide, which affect 20% or more of patients, are often limiting, frequently necessitating drug discontinuation. The FDA has placed a black-box warning on metoclopramide because of the risk of side effects, including tardive dyskinesia (albeit rare). Risk factors for developing dystonias appear to include female sex, higher medication dose, and older age. Hyperprolactinemia is another potential side effect and can lead to galactorrhea and menstrual irregularities. Metoclopramide has also been associated with QTc prolongation. Interactions with drugs that alter cytochrome P450-2D6 (CYP2D6) function should be considered.<sup><xref ref-type="bibr" rid="bibr45-0884533613491982">45</xref></sup> As with any medication, the potential risks should be reviewed in detail with patients prior to prescribing.</p>
</sec>
<sec id="section12-0884533613491982">
<title>Domperidone</title>
<p>Domperidone is a dopamine antagonist that has prokinetic and antiemetic effects similar to metoclopramide. Studies suggest equal efficacy compared with metoclopramide.<sup><xref ref-type="bibr" rid="bibr2-0884533613491982">2</xref></sup> Unlike metoclopramide, domperidone does not cross the blood-brain barrier and causes fewer central nervous system side effects. However, dry mouth, headaches, and symptoms related to hyperprolactinemia are seen. Domperidone may prolong the QTc interval and rarely causes cardiac arrhythmias. A baseline electrocardiogram is recommended prior initiating therapy, and the drug is withheld for a QTc &gt;470 milliseconds in men and &gt;450 milliseconds in women. Follow-up electrocardiogram on therapy should be considered. The recommended initial dose is 10 mg, 3 times per day, and this can be increased up to 20 mg, 4 times per day, 30 minutes before meals and at bedtime. Drug-drug interactions may occur with drugs that alter CYP2D6 function.<sup><xref ref-type="bibr" rid="bibr46-0884533613491982">46</xref></sup> Not approved for the management of gastroparesis, domperidone is available under a special program administered by the FDA.</p>
</sec>
<sec id="section13-0884533613491982">
<title>Erythromycin</title>
<p>Erythromycin mediates its prokinetic activities as an agonist of motilin, which is an endogenous hormone that stimulates gastric emptying. Erythromycin is most useful in acute settings when given intravenously at a dose of 3 mg/kg every 8 hours.<sup><xref ref-type="bibr" rid="bibr47-0884533613491982">47</xref></sup> When given orally, it can be effective at improving gastric emptying. Long-term use is often limited secondary to tachyphylaxis and side effects.<sup><xref ref-type="bibr" rid="bibr48-0884533613491982">48</xref></sup> Like metoclopramide, erythromycin is available in tablet or liquid formulations, with the latter favored in patients with significant gastroparesis. The overall dose range is 1–3 mg/kg. Clinically, 125–250 mg taken orally 2–4 times per day is recommended. Interactions are possible with drugs that interact with CYP3A4 metabolism. As with the other agents, this drug may be associated with prolongation of the QTc interval.</p>
</sec>
<sec id="section14-0884533613491982">
<title>Novel prokinetic agents</title>
<p>Given cardiac dysrhythmias associated with previous 5-HT<sub>4</sub> agonists, such as cisapride and tegaserod, newer prokinetics need to have greater selectivity to avoid cardiac complications. Velusetrag has a 500-fold selectivity and affinity to the 5-HT<sub>4</sub> receptor with no effect in the 5-HT cardiac receptors.<sup><xref ref-type="bibr" rid="bibr49-0884533613491982">49</xref></sup> Other promising prokinetics in development include the motilin agonist GSK962040<sup><xref ref-type="bibr" rid="bibr50-0884533613491982">50</xref></sup> and the ghrelin agonist RM-131.<sup><xref ref-type="bibr" rid="bibr51-0884533613491982">51</xref></sup> Future studies demonstrating efficacy in patients with gastroparesis are anticipated.</p>
</sec>
</sec>
<sec id="section15-0884533613491982">
<title>Antiemetics and Acupuncture</title>
<p>Although they have not been specifically tested in gastroparesis, antiemetics are often indicated given the nausea and vomiting that frequently accompany gastroparesis. No single antiemetic drug or class of drugs has emerged as the best option. Alternative therapies, such as ginger, as used in several clinical situations (including nausea associated with pregnancy, chemotherapy, and functional gastrointestinal disorders) may be useful given its antiemetic properties.<sup><xref ref-type="bibr" rid="bibr52-0884533613491982">52</xref></sup> Ultimately, the decision should be based on patient response, tolerance, and cost. Transdermal drug delivery of antiemetics (eg, scopolamine patch, granisetron transdermal system) can be considered when more traditional treatments have failed and if oral or rectal delivery is limited.</p>
<p>Acupuncture, which has been associated with reduction of symptoms and improved gastric emptying,<sup><xref ref-type="bibr" rid="bibr53-0884533613491982">53</xref>,<xref ref-type="bibr" rid="bibr54-0884533613491982">54</xref></sup> can be considered as an alternative therapy. A single-blinded, randomized pilot study evaluating the effects of electroacupuncture in patients with type 2 diabetes reported reduced gastroparesis symptom severity.<sup><xref ref-type="bibr" rid="bibr55-0884533613491982">55</xref></sup> Although not studied in gastroparesis, acupressure has been shown to decrease nausea in various patient populations.<sup><xref ref-type="bibr" rid="bibr56-0884533613491982">56</xref></sup> Other alternative therapies, such as biofeedback and hypnotherapy, have been used for the management of nausea in various disorders. One study suggested that behavioral treatments, such as autonomic training and directed imagery, may be efficacious in some patients with impaired gastric emptying and adrenergic dysfunction.<sup><xref ref-type="bibr" rid="bibr57-0884533613491982">57</xref></sup> There is minimal risk with these therapies, and, given that effectively managing symptoms is key, more rigorous trials in patients with gastroparesis are welcomed.</p>
</sec>
<sec id="section16-0884533613491982">
<title>Other Medications</title>
<p>Low-dose amitriptyline was shown to decrease the sensation of nausea in healthy volunteers.<sup><xref ref-type="bibr" rid="bibr58-0884533613491982">58</xref></sup> Accordingly, tricyclic antidepressants and other medications that may affect gastric sensation can be considered for refractory nausea and vomiting in gastroparesis. Open-label treatment trials have reported improved symptom control in patients with idiopathic and diabetic gastroparesis.<sup><xref ref-type="bibr" rid="bibr59-0884533613491982">59</xref>,<xref ref-type="bibr" rid="bibr60-0884533613491982">60</xref></sup> Although these agents used in low doses appear to have a minimal clinical impact on gastric emptying,<sup><xref ref-type="bibr" rid="bibr58-0884533613491982">58</xref></sup> tricyclic agents with lower anticholinergic activity (eg, nortriptyline) could be considered. A single report has shown mirtazapine, a 5-HT<sub>2</sub> receptor antagonist, to be efficacious in severe gastroparesis the is unresponsive to conventional prokinetic treatment.<sup><xref ref-type="bibr" rid="bibr61-0884533613491982">61</xref></sup> Azithromycin has been shown to stimulate antral activity similar to erythromycin.<sup><xref ref-type="bibr" rid="bibr62-0884533613491982">62</xref></sup> A recent study has demonstrated an increased risk of cardiovascular death in patients receiving azithromycin.<sup><xref ref-type="bibr" rid="bibr63-0884533613491982">63</xref></sup> Because studies of dose, formulation, patient tolerance, safety, and clinical efficacy in the management of gastroparesis are needed, azithromycin cannot be recommended at this time.</p>
</sec>
<sec id="section17-0884533613491982">
<title>Nutrition Support</title>
<p>Differences between calculated nutrition requirements and patient intake can be supplemented with nutrition support. Oral intake is the preferred route for nutrition and hydration. In most cases, if weight gain is the goal, an additional 500 kcal/d should be given. An additional 3500 kcal/wk will typically result in a weight gain of 1 pound or 0.45 kg/wk. In general, nutrition support will depend on the degree of gastrointestinal symptoms, the degree of malnutrition, and the response to nutrition interventions (which needs to be monitored, with adjustments to the program as needed). Patients with mild symptoms tend to respond well to oral supplements. In contrast, patients with more severe symptoms may need enteral access. Total parenteral nutrition should be reserved for refractory cases, where adequate nutrition cannot be maintained by other means.</p>
<sec id="section18-0884533613491982">
<title>Enteral alimentation</title>
<p>Enteral alimentation is indicated in patients with unintentional weight loss (&gt;5%–10% over a period of 3–6 months) and for patients who are unable to meet their caloric needs with diet and oral supplements. Consideration for earlier intervention can be given if the patient has persistent, severe symptoms and frequent hospitalizations, as these patients are considered at high risk of worsening malnutrition. Close follow-up by a nutrition support clinician to assess weight changes, fluid retention, and oral intake is important when one is considering the need for enteral feedings.</p>
<p>Postpyloric (particularly jejunal) feeding is preferable to gastric feeding in patients with gastroparesis.<sup><xref ref-type="bibr" rid="bibr64-0884533613491982">64</xref></sup> Feedings delivered directly into the stomach can prove problematic for patients with gastroparesis secondary to accompanying motor and/or sensory abnormalities. This can exacerbate symptoms and interfere with achievement of a patient’s caloric goals. Jejunal feedings can improve hydration and nutrition, can minimize hospital stays, and are generally well tolerated. It is customary to first place a nasoenteric tube to ensure that patients will be able to tolerate the tube feeds. However, long-term use of nasoenteric tubes is limited due to nasal irritation, increased risk of sinusitis, and possible exacerbation of gastrointestinal symptoms.</p>
<p>Placement of a jejunostomy tube can be performed by surgical methods, by endoscopic procedures, and, more commonly, with fluoroscopic guidance by interventional radiology. The rate of feedings through a direct jejunal tube should be increased slowly until the nutrition goal is reached. We prefer using nocturnal feeding with an infusion pump while the patient sleeps. Bolus or gravity feedings into the jejunum are not generally recommended as patients are often intolerant, leading to impaired nutrition. Nocturnal feedings with a pump permit the patient to be disconnected from the tube during the day, allowing patients increased independence with decreased daytime satiety. These factors likely increase overall compliance. Blood glucose levels in patients with diabetes receiving nocturnal feedings need to be assessed, with appropriate adjustments to their mediation regimen as needed.</p>
<p>Aspiration of the tube for assessment of tolerance to feedings (as is generally performed in gastrostomy feedings) is not recommended, but frequent flushes with water are mandatory to avoid tube dysfunction and clogging. Individualizing the infusion rate and duration of nocturnal feedings leads to improved compliance. Although a discussion of different formulas that can be used is beyond the scope of this review, we use standard polymeric formulas with a concentrated calorie density (1.2–1.5 kcal/mL). As most enteral formulas contain approximately 84% free water, flushes should make up the difference if the deficit is not consumed orally. High-calorie formulas can be used to decrease volume of infusion, but they are not needed in general, as these patients require hydration that can be achieved with low-density formulas.</p>
<p>A more recent practice is to place a combination gastrostomy-jejunostomy tube. The gastrostomy tube port is available for medications and to decompress the gut and jejunostomy tube port for feeding. This approach has both advantages and disadvantages. The gastrostomy tube for intermittent venting may assist in symptom control and administration of certain medications, whereas the jejunostomy tube allows direct feeding into the small intestine. It is our experience that direct jejunal tubes enjoy the benefit of better durability than the smaller catheters used in combined gastrostomy-jejunostomy tubes, which often migrate back into the stomach, particularly in patients with recurrent vomiting. Furthermore, if patients decompress the stomach frequently, hoping to reduce symptoms, this may contribute to dehydration, electrolyte imbalances, and even metabolic alkalosis. We normally do not recommend the placement of a gastrostomy tube for gastric decompression or venting. We reserve this practice for patients with a more global motility disturbance, such as intestinal pseudo-obstruction.</p>
<p>Once gastrointestinal access has been achieved, it is important for the treating clinician to work closely with the dietician and nutrition support team to provide appropriate assessment of nutrition status, any deficiencies, and management details. Considering the needs of the patient, the support team can choose the most appropriate formula and form of delivery for the patient. Education of the patient and family is very important to prevent infections, tube dysfunction, and clogging of the tube to avoid unnecessary tube replacements. Last, close follow-up is recommended to assess tolerance and compliance of nutrition recommendations to ensure that patients’ needs are being met.</p>
</sec>
<sec id="section19-0884533613491982">
<title>Parenteral nutrition</title>
<p>Parental nutrition is occasionally needed during acute exacerbations requiring hospitalization and often in the chronic setting when there is concomitant small bowel dysmotility that limits use of the gut (eg, intestinal pseudo-obstruction). Patients may develop an acute exacerbation of symptoms for various reasons, such as infection. Clinical deterioration can lead rapidly to complications. Every attempt should be made to continue with enteral feedings. Even if a patient requires parenteral nutrition, it should be considered temporary, with every attempt made to reestablish enteral feeding. Because of an increased risk for infection and venous complications, parenteral nutrition should be considered as a last resort, when enteric feeding has proved unsuccessful.</p>
</sec>
</sec>
<sec id="section20-0884533613491982">
<title>Botulinum Toxin (Botox)</title>
<p>Botox is a neurotoxin that inhibits acetylcholine release from synaptic vesicles at synaptic junctions.<sup><xref ref-type="bibr" rid="bibr65-0884533613491982">65</xref></sup> It is effective in the treatment of disorders of skeletal and smooth muscle hypertonicity.<sup><xref ref-type="bibr" rid="bibr66-0884533613491982">66</xref></sup> Initial open-label studies in patients with gastroparesis demonstrated improved gastric emptying and symptoms following intrapyloric injection of 100–200 units of botox.<sup><xref ref-type="bibr" rid="bibr67-0884533613491982">67</xref>,<xref ref-type="bibr" rid="bibr68-0884533613491982">68</xref></sup> Manometric studies also showed decreased pylorospasm.<sup><xref ref-type="bibr" rid="bibr68-0884533613491982">68</xref></sup> Larger retrospective studies suggested response rates of around 50%, symptomatic improvement for about 5 months, and more success with higher doses.<sup><xref ref-type="bibr" rid="bibr69-0884533613491982">69</xref>.<xref ref-type="bibr" rid="bibr70-0884533613491982">70</xref></sup> However, 2 double-blind, placebo-controlled studies showed no improvement in symptoms with botox compared with placebo.<sup><xref ref-type="bibr" rid="bibr71-0884533613491982">71</xref>,<xref ref-type="bibr" rid="bibr72-0884533613491982">72</xref></sup> Mechanistic studies showed no correlation between symptom improvement and gastric emptying parameters. Although the treatment appears safe and clinical experience may suggest that some patients experience clinical improvement, routine use of intrapyloric botox injection cannot be recommended based on the results of larger, randomized controlled trials.<sup><xref ref-type="bibr" rid="bibr73-0884533613491982">73</xref></sup></p>
</sec>
<sec id="section21-0884533613491982">
<title>Gastric Electrical Stimulation</title>
<p>Gastric electrical stimulation (GES) delivers high-frequency, low-amplitude stimulation via electrodes implanted in the gastric muscle.<sup><xref ref-type="bibr" rid="bibr74-0884533613491982">74</xref></sup> Based on studies showing improvement in clinical symptoms and quality of life in certain patient subgroups,<sup><xref ref-type="bibr" rid="bibr75-0884533613491982">75</xref>,<xref ref-type="bibr" rid="bibr76-0884533613491982">76</xref></sup> the GES device was approved by the FDA as a humanitarian device exemption in 2000.<sup><xref ref-type="bibr" rid="bibr77-0884533613491982">77</xref></sup> An open-label study of GES found a short-term improvement in weight, body mass index, and albumin with maintained weight in the long term.<sup><xref ref-type="bibr" rid="bibr78-0884533613491982">78</xref></sup> In general, meta-analyses have suggested improvement in patient outcomes.<sup><xref ref-type="bibr" rid="bibr79-0884533613491982">79</xref>,<xref ref-type="bibr" rid="bibr80-0884533613491982">80</xref></sup> However, most supportive data come from open-label, nonrandomized trials and small case series. In addition to lacking true control subjects, many studies are limited by relatively short follow-up, and there is an unclear natural history of gastroparesis. Therefore, the generalizability of GES in the standard gastroparesis population remains unclear. Patients with diabetic gastroparesis appear to be more responsive to GES than those in the idiopathic or postsurgical groups.<sup><xref ref-type="bibr" rid="bibr80-0884533613491982">80</xref></sup> Patients with pain predominance and those receiving narcotics do not respond as well to GES.</p>
<p>GES does not appear to reliably accelerate gastric emptying, and clinical response is not associated with gastric emptying parameters. GES may function more as a neurostimulating device altering the sensory function of the afferent nerves rather than “pacing” the stomach emptying. Although the data do not support routine use, GES may be considered for compassionate use in patients with refractory nausea and vomiting. Temporary stimulation with an endoscopic gastric lead has been proposed to identify those patients who may respond to GES,<sup><xref ref-type="bibr" rid="bibr81-0884533613491982">81</xref></sup> but this practice needs further evaluation before it can be recommended. Because complications, including surgical problems, pocket infection, and lead migration, may occur in up to 10% of patients, the role of GES needs to be cautiously assessed. Issues regarding availability of follow-up after implantation (including adjustments of the device settings, replacement of batteries, etc) should also be considered.</p>
</sec>
<sec id="section22-0884533613491982">
<title>Bezoar Management</title>
<p>Gastric bezoars are typically composed of retained food debris within the stomach. A bezoar limits nutrition intake and can be complicated by gastrointestinal bleeding, obstruction, and perforation. Bezoars can be mechanically disrupted endoscopically as well as enzymatically digested, depending on the composition of the bezoar. Agents frequently tried include papain, cellulose, and N-acetylcysteine.</p>
</sec>
<sec id="section23-0884533613491982">
<title>Surgery</title>
<p>Aside from placement of feeding or decompression tubes, the role of surgery in the treatment of gastroparesis is limited. As outlined above, postpyloric tubes are recommended for feeding. In an open-label study, patients with refractory idiopathic gastroparesis reported improvement following placement of a venting percutaneous gastrostomy.<sup><xref ref-type="bibr" rid="bibr82-0884533613491982">82</xref></sup> We favor limiting the use of a gastrostomy tube for decompression to cases in which there is prominent distention in the stomach or small bowel (eg, intestinal pseudo-obstruction).<sup><xref ref-type="bibr" rid="bibr83-0884533613491982">83</xref></sup> A recent study suggesting improvement following pyloroplasty<sup><xref ref-type="bibr" rid="bibr84-0884533613491982">84</xref></sup> needs further evaluation with additional studies to look at long-term outcomes and ideal patient selection. Gastrectomy is reserved for a very highly select group of patients with severe gastroparesis that is refractory to medical management, and this procedure seems to be most useful in patients with gastroparesis secondary to a previous partial gastric resection.<sup><xref ref-type="bibr" rid="bibr85-0884533613491982">85</xref></sup> There are limited data on the surgical management of diabetic or idiopathic gastroparesis, and meaningful conclusions cannot be made at this time. In patients with Roux stasis syndrome, there is delayed transit through the stomach and Roux limb following a Roux-en-Y gastrojejunostomy.<sup><xref ref-type="bibr" rid="bibr86-0884533613491982">86</xref><xref ref-type="bibr" rid="bibr87-0884533613491982"/>-<xref ref-type="bibr" rid="bibr88-0884533613491982">88</xref></sup> It is felt that a Roux limb with a length &gt;45 cm predisposes to this condition, and surgical revision may be indicated if there is an unsatisfactory response to promotility agents.</p>
</sec>
<sec id="section24-0884533613491982">
<title>Other Considerations</title>
<p>As elevated blood glucose levels delay gastric emptying and may aggravate symptoms, optimizing glycemic control is essential in patients with diabetes.<sup><xref ref-type="bibr" rid="bibr2-0884533613491982">2</xref></sup> As outlined above, the use of certain diabetes medications (eg, amylin and GLP-1 analogs) that can delay gastric emptying should be evaluated. Other medications for diabetes may be considered before a diagnosis of gastroparesis is made and medical therapies are considered. Constipation may negatively affect upper gut function via inhibitory cologastric reflexes. Further, suppression of defecation has been shown to slow gastric emptying.<sup><xref ref-type="bibr" rid="bibr89-0884533613491982">89</xref></sup> Constipated patients have an increase in dyspepsia, abdominal cramping, bloating, flatulence, heartburn, nausea, and vomiting. Therefore, constipation should be assessed and managed accordingly. Gastroparesis may also aggravate gastroesophageal reflux, which should be managed accordingly. Last, small bowel bacterial overgrowth may complicate patients with intestinal motility disorders, affecting symptoms and nutrition status. Antibiotics should be considered in the appropriate clinical setting.</p>
</sec>
</sec>
<sec id="section25-0884533613491982">
<title>Summary</title>
<p>Gastroparesis and general symptoms of nausea, vomiting, and dyspepsia are difficult to diagnose and treat. Symptoms may be related to both motor and sensory dysfunction. Once obvious causes are excluded (including medications like opiates and anticholinergic agents), targeting therapy to the specific cause of the symptoms while considering possible complications is essential. This includes frequently associated findings, ranging from gastroesophageal reflux to constipation. Protein-calorie malnutrition is common and often overlooked in patients with gastroparesis. A focus on dietary adjustments is a first step, accompanied by prokinetics or medications that modulate visceral sensation and aid in symptom management. Supplemental nutrition can be considered as needed, with the enteral route favored over parenteral route. There is a limited role for surgery in gastroparesis. Novel diagnostic strategies and therapeutic alternatives are emerging, and more rigorous studies that clarify their role in gastroparesis are anticipated.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0884533613491982">
<label>1.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>DeVault</surname><given-names>KR</given-names></name>
<name><surname>Bouras</surname><given-names>EP</given-names></name>
<name><surname>Talley</surname><given-names>NJ</given-names></name>
</person-group>. <article-title>Esophageal and gastric motor function</article-title>. In: <person-group person-group-type="editor">
<name><surname>Talley</surname><given-names>NJ</given-names></name>
</person-group>, ed. <source>Practical Gastroenterology and Hepatology</source>. <volume>Vol. 1</volume>. <publisher-loc>Oxford, UK</publisher-loc>: <publisher-loc>Wiley-Blackwell</publisher-loc>; <year>2010. 9-15</year>.</citation>
</ref>
<ref id="bibr2-0884533613491982">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Camilleri</surname><given-names>M</given-names></name>
<name><surname>Parkman</surname><given-names>HP</given-names></name>
<name><surname>Shafi</surname><given-names>MA</given-names></name>
<name><surname>Abell</surname><given-names>TL</given-names></name>
<name><surname>Gerson</surname><given-names>L</given-names></name>
</person-group>. <article-title>Clinical guideline: management of gastroparesis</article-title>. <source>Am J Gastroenterol</source>. <year>2013</year>;<volume>108</volume>(<issue>1</issue>):<fpage>18</fpage>-<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr3-0884533613491982">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Brien</surname><given-names>MD</given-names></name>
<name><surname>Bruce</surname><given-names>BK</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name>
</person-group>. <article-title>The rumination syndrome: clinical features rather than manometric diagnosis</article-title>. <source>Gastroenterology</source>. <year>1995</year>;<volume>108</volume>(<issue>4</issue>):<fpage>1024</fpage>-<lpage>1029</lpage>.</citation>
</ref>
<ref id="bibr4-0884533613491982">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hyett</surname><given-names>B</given-names></name>
<name><surname>Martinez</surname><given-names>FJ</given-names></name>
<name><surname>Gill</surname><given-names>BM</given-names></name><etal/>
</person-group>. <article-title>Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis</article-title>. <source>Gastroenterology</source>. <year>2009</year>;<volume>137</volume>(<issue>2</issue>):<fpage>445</fpage>-<lpage>452</lpage>.</citation>
</ref>
<ref id="bibr5-0884533613491982">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Horowitz</surname><given-names>M</given-names></name>
<name><surname>Harding</surname><given-names>PE</given-names></name>
<name><surname>Maddox</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Gastric and oesophageal emptying in insulin-dependent diabetes mellitus</article-title>. <source>J Gastroenterol Hepatol</source>. <year>1986</year>;<volume>1</volume>:<fpage>97</fpage>-<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr6-0884533613491982">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Keshavarzian</surname><given-names>A</given-names></name>
<name><surname>Iber</surname><given-names>FL</given-names></name>
<name><surname>Vaeth</surname><given-names>J</given-names></name>
</person-group>. <article-title>Gastric emptying in patients with insulin-requiring diabetes mellitus</article-title>. <source>Am J Gastroenterol</source>. <year>1987</year>;<volume>82</volume>(<issue>1</issue>):<fpage>29</fpage>-<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr7-0884533613491982">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Horowitz</surname><given-names>M</given-names></name>
<name><surname>Harding</surname><given-names>PE</given-names></name>
<name><surname>Maddox</surname><given-names>AF</given-names></name><etal/>
</person-group>. <article-title>Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus</article-title>. <source>Diabetologia</source>. <year>1989</year>;<volume>32</volume>(<issue>3</issue>):<fpage>151</fpage>-<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr8-0884533613491982">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wegener</surname><given-names>M</given-names></name>
<name><surname>Borsch</surname><given-names>G</given-names></name>
<name><surname>Schaffstein</surname><given-names>J</given-names></name>
<name><surname>Luerweg</surname><given-names>C</given-names></name>
<name><surname>Leverkus</surname><given-names>F</given-names></name>
</person-group>. <article-title>Gastrointestinal transit disorders in patients with insulin-treated diabetes mellitus</article-title>. <source>Dig Dis</source>. <year>1990</year>;<volume>8</volume>(<issue>1</issue>):<fpage>23</fpage>-<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr9-0884533613491982">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mearin</surname><given-names>F</given-names></name>
<name><surname>Malagelada</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Gastroparesis and dyspepsia in patients with diabetes mellitus</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>1995</year>;<volume>7</volume>(<issue>8</issue>):<fpage>717</fpage>-<lpage>723</lpage>.</citation>
</ref>
<ref id="bibr10-0884533613491982">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Choung</surname><given-names>RS</given-names></name>
<name><surname>Locke</surname><given-names>GR</given-names><suffix>III</suffix></name>
<name><surname>Schleck</surname><given-names>CD</given-names></name>
<name><surname>Zinsmeister</surname><given-names>AR</given-names></name>
<name><surname>Melton</surname><given-names>LJ</given-names><suffix>III</suffix></name>
<name><surname>Talley</surname><given-names>NJ</given-names></name>
</person-group>. <article-title>Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population</article-title>. <source>Am J Gastroenterol</source>. <year>2012</year>;<volume>107</volume>(<issue>1</issue>):<fpage>82</fpage>-<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr11-0884533613491982">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dyck</surname><given-names>PJ</given-names></name>
<name><surname>Kratz</surname><given-names>KM</given-names></name>
<name><surname>Karnes</surname><given-names>JL</given-names></name><etal/>
</person-group>. <article-title>The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study</article-title>. <source>Neurology</source>. <year>1993</year>;<volume>43</volume>(<issue>4</issue>):<fpage>817</fpage>-<lpage>824</lpage>.</citation>
</ref>
<ref id="bibr12-0884533613491982">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Feldman</surname><given-names>M</given-names></name>
<name><surname>Schiller</surname><given-names>LR</given-names></name>
</person-group>. <article-title>Disorders of gastrointestinal motility associated with diabetes mellitus</article-title>. <source>Ann Intern Med</source>. <year>1983</year>;<volume>98</volume>(<issue>3</issue>):<fpage>378</fpage>-<lpage>384</lpage>.</citation>
</ref>
<ref id="bibr13-0884533613491982">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>He</surname><given-names>CL</given-names></name>
<name><surname>Soffer</surname><given-names>EE</given-names></name>
<name><surname>Ferris</surname><given-names>CD</given-names></name>
<name><surname>Walsh</surname><given-names>RM</given-names></name>
<name><surname>Szurszewski</surname><given-names>JH</given-names></name>
<name><surname>Farrugia</surname><given-names>G</given-names></name>
</person-group>. <article-title>Loss of interstitial cells of cajal and inhibitory innervation in insulin-dependent diabetes</article-title>. <source>Gastroenterology</source>. <year>2001</year>;<volume>121</volume>(<issue>2</issue>):<fpage>427</fpage>-<lpage>434</lpage>.</citation>
</ref>
<ref id="bibr14-0884533613491982">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mearin</surname><given-names>F</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name>
<name><surname>Malagelada</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Pyloric dysfunction in diabetics with recurrent nausea and vomiting</article-title>. <source>Gastroenterology</source>. <year>1986</year>;<volume>90</volume>(<issue>6</issue>):<fpage>1919</fpage>-<lpage>1925</lpage>.</citation>
</ref>
<ref id="bibr15-0884533613491982">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parkman</surname><given-names>HP</given-names></name>
<name><surname>Yates</surname><given-names>K</given-names></name>
<name><surname>Hasler</surname><given-names>WL</given-names></name><etal/>
</person-group>. <article-title>Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity</article-title>. <source>Gastroenterology</source>. <year>2011</year>;<volume>140</volume>(<issue>1</issue>):<fpage>101</fpage>-<lpage>115</lpage>.</citation>
</ref>
<ref id="bibr16-0884533613491982">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parkman</surname><given-names>HP</given-names></name>
<name><surname>Yates</surname><given-names>K</given-names></name>
<name><surname>Hasler</surname><given-names>WL</given-names></name><etal/>
</person-group>. <article-title>Similarities and differences between diabetic and idiopathic gastroparesis</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2011</year>;<volume>9</volume>(<issue>12</issue>):<fpage>1056</fpage>-<lpage>1064</lpage>; quiz e133-e134.</citation>
</ref>
<ref id="bibr17-0884533613491982">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bityutskiy</surname><given-names>LP</given-names></name>
<name><surname>Soykan</surname><given-names>I</given-names></name>
<name><surname>McCallum</surname><given-names>RW</given-names></name>
</person-group>. <article-title>Viral gastroparesis: a subgroup of idiopathic gastroparesis—clinical characteristics and long-term outcomes</article-title>. <source>Am J Gastroenterol</source>. <year>1997</year>;<volume>92</volume>(<issue>9</issue>):<fpage>1501</fpage>-<lpage>1504</lpage>.</citation>
</ref>
<ref id="bibr18-0884533613491982">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soykan</surname><given-names>I</given-names></name>
<name><surname>Sivri</surname><given-names>B</given-names></name>
<name><surname>Sarosiek</surname><given-names>I</given-names></name>
<name><surname>Kiernan</surname><given-names>B</given-names></name>
<name><surname>McCallum</surname><given-names>RW</given-names></name>
</person-group>. <article-title>Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis</article-title>. <source>Dig Dis Sci</source>. <year>1998</year>;<volume>43</volume>(<issue>11</issue>):<fpage>2398</fpage>-<lpage>2404</lpage>.</citation>
</ref>
<ref id="bibr19-0884533613491982">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vassallo</surname><given-names>M</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name>
<name><surname>Caron</surname><given-names>BL</given-names></name>
<name><surname>Low</surname><given-names>PA</given-names></name>
</person-group>. <article-title>Gastrointestinal motor dysfunction in acquired selective cholinergic dysautonomia associated with infectious mononucleosis</article-title>. <source>Gastroenterology</source>. <year>1991</year>;<volume>100</volume>(<issue>1</issue>):<fpage>252</fpage>-<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr20-0884533613491982">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abell</surname><given-names>TL</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name>
<name><surname>Donohoe</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine</article-title>. <source>Am J Gastroenterol</source>. <year>2008</year>;<volume>103</volume>(<issue>3</issue>):<fpage>753</fpage>-<lpage>763</lpage>.</citation>
</ref>
<ref id="bibr21-0884533613491982">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuo</surname><given-names>B</given-names></name>
<name><surname>McCallum</surname><given-names>RW</given-names></name>
<name><surname>Koch</surname><given-names>KL</given-names></name><etal/>
</person-group>. <article-title>Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2008</year>;<volume>27</volume>(<issue>2</issue>):<fpage>186</fpage>-<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr22-0884533613491982">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ghoos</surname><given-names>YF</given-names></name>
<name><surname>Maes</surname><given-names>BD</given-names></name>
<name><surname>Geypens</surname><given-names>BJ</given-names></name><etal/>
</person-group>. <article-title>Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test</article-title>. <source>Gastroenterology</source>. <year>1993</year>;<volume>104</volume>(<issue>6</issue>):<fpage>1640</fpage>-<lpage>1647</lpage>.</citation>
</ref>
<ref id="bibr23-0884533613491982">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Szarka</surname><given-names>LA</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name>
<name><surname>Vella</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2008</year>;<volume>6</volume>(<issue>6</issue>):<fpage>635</fpage>-<lpage>643 e1</lpage>.</citation>
</ref>
<ref id="bibr24-0884533613491982">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Camilleri</surname><given-names>M</given-names></name>
<name><surname>Hasler</surname><given-names>WL</given-names></name>
<name><surname>Parkman</surname><given-names>HP</given-names></name>
<name><surname>Quigley</surname><given-names>EM</given-names></name>
<name><surname>Soffer</surname><given-names>E</given-names></name>
</person-group>. <article-title>Measurement of gastrointestinal motility in the GI laboratory</article-title>. <source>Gastroenterology</source>. <year>1998</year>;<volume>115</volume>(<issue>3</issue>):<fpage>747</fpage>-<lpage>762</lpage>.</citation>
</ref>
<ref id="bibr25-0884533613491982">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Camilleri</surname><given-names>M</given-names></name>
</person-group>. <article-title>Study of human gastroduodenojejunal motility: applied physiology in clinical practice</article-title>. <source>Dig Dis Sci</source>. <year>1993</year>;<volume>38</volume>(<issue>5</issue>):<fpage>785</fpage>-<lpage>794</lpage>.</citation>
</ref>
<ref id="bibr26-0884533613491982">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Camilleri</surname><given-names>M</given-names></name>
<name><surname>Bharucha</surname><given-names>AE</given-names></name>
<name><surname>di Lorenzo</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>American Neurogastro-enterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice</article-title>. <source>Neurogastroenterol Motil</source>. <year>2008</year>;<volume>20</volume>(<issue>12</issue>):<fpage>1269</fpage>-<lpage>1282</lpage>.</citation>
</ref>
<ref id="bibr27-0884533613491982">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Schepper</surname><given-names>HU</given-names></name>
<name><surname>Cremonini</surname><given-names>F</given-names></name>
<name><surname>Chitkara</surname><given-names>D</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name>
</person-group>. <article-title>Assessment of gastric accommodation: overview and evaluation of current methods</article-title>. <source>Neurogastroenterol Motil</source>. <year>2004</year>;<volume>16</volume>(<issue>3</issue>):<fpage>275</fpage>-<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr28-0884533613491982">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bouras</surname><given-names>EP</given-names></name>
<name><surname>Delgado-Aros</surname><given-names>S</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication: single photon emission computed tomography</article-title>. <source>Gut</source>. <year>2002</year>;<volume>51</volume>(<issue>6</issue>):<fpage>781</fpage>-<lpage>786</lpage>.</citation>
</ref>
<ref id="bibr29-0884533613491982">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chial</surname><given-names>HJ</given-names></name>
<name><surname>Camilleri</surname><given-names>C</given-names></name>
<name><surname>Delgado-Aros</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health</article-title>. <source>Neurogastroenterol Motil</source>. <year>2002</year>;<volume>14</volume>(<issue>3</issue>):<fpage>249</fpage>-<lpage>253</lpage>.</citation>
</ref>
<ref id="bibr30-0884533613491982">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>DY</given-names></name>
<name><surname>Myung</surname><given-names>SJ</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name>
</person-group>. <article-title>Novel testing of human gastric motor and sensory functions: rationale, methods, and potential applications in clinical practice</article-title>. <source>Am J Gastroenterol</source>. <year>2000</year>;<volume>95</volume>(<issue>12</issue>):<fpage>3365</fpage>-<lpage>3373</lpage>.</citation>
</ref>
<ref id="bibr31-0884533613491982">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kolterman</surname><given-names>OG</given-names></name>
<name><surname>Kim</surname><given-names>DD</given-names></name>
<name><surname>Shen</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus</article-title>. <source>Am J Health Syst Pharm</source>. <year>2005</year>;<volume>62</volume>(<issue>2</issue>):<fpage>173</fpage>-<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr32-0884533613491982">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vella</surname><given-names>A</given-names></name>
<name><surname>Lee</surname><given-names>JS</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus</article-title>. <source>Neurogastroenterol Motil</source>. <year>2002</year>;<volume>14</volume>(<issue>2</issue>):<fpage>123</fpage>-<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr33-0884533613491982">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tack</surname><given-names>J</given-names></name>
<name><surname>Talley</surname><given-names>NJ</given-names></name>
</person-group>. <article-title>Functional dyspepsia—symptoms, definitions and validity of the Rome III criteria</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. <year>2013</year>;<volume>10</volume>(<issue>3</issue>):<fpage>134</fpage>-<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr34-0884533613491982">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quartero</surname><given-names>AO</given-names></name>
<name><surname>de Wit</surname><given-names>NJ</given-names></name>
<name><surname>Lodder</surname><given-names>AC</given-names></name>
<name><surname>Numans</surname><given-names>ME</given-names></name>
<name><surname>Smout</surname><given-names>AJ</given-names></name>
<name><surname>Hoes</surname><given-names>AW</given-names></name>
</person-group>. <article-title>Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis</article-title>. <source>Dig Dis Sci</source>. <year>1998</year>;<volume>43</volume>(<issue>9</issue>):<fpage>2028</fpage>-<lpage>2033</lpage>.</citation>
</ref>
<ref id="bibr35-0884533613491982">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stanghellini</surname><given-names>V</given-names></name>
<name><surname>Tosetti</surname><given-names>C</given-names></name>
<name><surname>Paternico</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia</article-title>. <source>Gastroenterology</source>. <year>1996</year>;<volume>110</volume>(<issue>4</issue>):<fpage>1036</fpage>-<lpage>1042</lpage>.</citation>
</ref>
<ref id="bibr36-0884533613491982">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parkman</surname><given-names>HP</given-names></name>
<name><surname>Yates</surname><given-names>KP</given-names></name>
<name><surname>Hasler</surname><given-names>WL</given-names></name><etal/>
</person-group>. <article-title>Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis</article-title>. <source>Gastroenterology</source>. <year>2011</year>;<volume>141</volume>(<issue>2</issue>):<fpage>486</fpage>-<lpage>498</lpage>, 98 e1-7.</citation>
</ref>
<ref id="bibr37-0884533613491982">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bouras</surname><given-names>EP</given-names></name>
<name><surname>Scolapio</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Gastric motility disorders: management that optimizes nutritional status</article-title>. <source>J Clin Gastroenterol</source>. <year>2004</year>;<volume>38</volume>(<issue>7</issue>):<fpage>549</fpage>-<lpage>557</lpage>.</citation>
</ref>
<ref id="bibr38-0884533613491982">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Camilleri</surname><given-names>M</given-names></name>
</person-group>. <article-title>Appraisal of medium- and long-term treatment of gastroparesis and chronic intestinal dysmotility</article-title>. <source>Am J Gastroenterol</source>. <year>1994</year>;<volume>89</volume>(<issue>10</issue>):<fpage>1769</fpage>-<lpage>1774</lpage>.</citation>
</ref>
<ref id="bibr39-0884533613491982">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ogorek</surname><given-names>CP</given-names></name>
<name><surname>Davidson</surname><given-names>L</given-names></name>
<name><surname>Fisher</surname><given-names>RS</given-names></name>
<name><surname>Krevsky</surname><given-names>B</given-names></name>
</person-group>. <article-title>Idiopathic gastroparesis is associated with a multiplicity of severe dietary deficiencies</article-title>. <source>Am J Gastroenterol</source>. <year>1991</year>;<volume>86</volume>(<issue>4</issue>):<fpage>423</fpage>-<lpage>448</lpage>.</citation>
</ref>
<ref id="bibr40-0884533613491982">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rao</surname><given-names>AS</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name>
</person-group>. <article-title>Review article: metoclopramide and tardive dyskinesia</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2010</year>;<volume>31</volume>(<issue>1</issue>):<fpage>11</fpage>-<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr41-0884533613491982">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Erbas</surname><given-names>T</given-names></name>
<name><surname>Varoglu</surname><given-names>E</given-names></name>
<name><surname>Erbas</surname><given-names>B</given-names></name>
<name><surname>Tastekin</surname><given-names>G</given-names></name>
<name><surname>Akalin</surname><given-names>S</given-names></name>
</person-group>. <article-title>Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis</article-title>. <source>Diabetes Care</source>. <year>1993</year>;<volume>16</volume>(<issue>11</issue>):<fpage>1511</fpage>-<lpage>1514</lpage>.</citation>
</ref>
<ref id="bibr42-0884533613491982">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Longstreth</surname><given-names>GF</given-names></name>
<name><surname>Malagelada</surname><given-names>JR</given-names></name>
<name><surname>Kelly</surname><given-names>KA</given-names></name>
</person-group>. <article-title>Metoclopramide stimulation of gastric motility and emptying in diabetic gastroparesis</article-title>. <source>Ann Intern Med</source>. <year>1977</year>;<volume>86</volume>(<issue>2</issue>):<fpage>195</fpage>-<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr43-0884533613491982">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McCallum</surname><given-names>RW</given-names></name>
<name><surname>Ricci</surname><given-names>DA</given-names></name>
<name><surname>Rakatansky</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis</article-title>. <source>Diabetes Care</source>. <year>1983</year>;<volume>6</volume>(<issue>5</issue>):<fpage>463</fpage>-<lpage>467</lpage>.</citation>
</ref>
<ref id="bibr44-0884533613491982">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Snape</surname><given-names>WJ</given-names><suffix>Jr.</suffix></name>
<name><surname>Battle</surname><given-names>WM</given-names></name>
<name><surname>Schwartz</surname><given-names>SS</given-names></name>
<name><surname>Braunstein</surname><given-names>SN</given-names></name>
<name><surname>Goldstein</surname><given-names>HA</given-names></name>
<name><surname>Alavi</surname><given-names>A</given-names></name>
</person-group>. <article-title>Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial</article-title>. <source>Ann Intern Med</source>. <year>1982</year>;<volume>96</volume>(<issue>4</issue>):<fpage>444</fpage>-<lpage>446</lpage>.</citation>
</ref>
<ref id="bibr45-0884533613491982">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parkman</surname><given-names>HP</given-names></name>
<name><surname>Mishra</surname><given-names>A</given-names></name>
<name><surname>Jacobs</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters</article-title>. <source>J Clin Gastroenterol</source>. <year>2012</year>;<volume>46</volume>(<issue>6</issue>):<fpage>494</fpage>-<lpage>503</lpage>.</citation>
</ref>
<ref id="bibr46-0884533613491982">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parkman</surname><given-names>HP</given-names></name>
<name><surname>Jacobs</surname><given-names>MR</given-names></name>
<name><surname>Mishra</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects</article-title>. <source>Dig Dis Sci</source>. <year>2011</year>;<volume>56</volume>(<issue>1</issue>):<fpage>115</fpage>-<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr47-0884533613491982">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Janssens</surname><given-names>J</given-names></name>
<name><surname>Peeters</surname><given-names>TL</given-names></name>
<name><surname>Vantrappen</surname><given-names>G</given-names></name><etal/>
</person-group>. <article-title>Improvement of gastric emptying in diabetic gastroparesis by erythromycin: preliminary studies</article-title>. <source>N Engl J Med</source>. <year>1990</year>;<volume>322</volume>(<issue>15</issue>):<fpage>1028</fpage>-<lpage>1031</lpage>.</citation>
</ref>
<ref id="bibr48-0884533613491982">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Richards</surname><given-names>RD</given-names></name>
<name><surname>Davenport</surname><given-names>K</given-names></name>
<name><surname>McCallum</surname><given-names>RW</given-names></name>
</person-group>. <article-title>The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin</article-title>. <source>Am J Gastroenterol</source>. <year>1993</year>;<volume>88</volume>(<issue>2</issue>):<fpage>203</fpage>-<lpage>207</lpage>.</citation>
</ref>
<ref id="bibr49-0884533613491982">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vazquez Roque</surname><given-names>M</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name>
</person-group>. <article-title>Velusetrag</article-title>. <source>Drugs Future</source>. <year>2011</year>;<volume>36: 447-454</volume>.</citation>
</ref>
<ref id="bibr50-0884533613491982">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanger</surname><given-names>GJ</given-names></name>
<name><surname>Westaway</surname><given-names>SM</given-names></name>
<name><surname>Barnes</surname><given-names>AA</given-names></name><etal/>
</person-group>. <article-title>GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility</article-title>. <source>Neurogastroenterol Motil</source>. <year>2009</year>;<volume>21</volume>(<issue>6</issue>):<fpage>657</fpage>-<lpage>664</lpage>, e30-1.</citation>
</ref>
<ref id="bibr51-0884533613491982">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shin</surname><given-names>A</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name>
<name><surname>Busciglio</surname><given-names>I</given-names></name><etal/>
</person-group>. <article-title>Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics</article-title>. <source>Diabetes Care</source>. <year>2013</year>;<volume>36</volume>(<issue>1</issue>):<fpage>41</fpage>-<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr52-0884533613491982">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walstab</surname><given-names>J</given-names></name>
<name><surname>Kruger</surname><given-names>D</given-names></name>
<name><surname>Stark</surname><given-names>T</given-names></name><etal/>
</person-group>. <article-title>Ginger and its pungent constituents non-competitively inhibit activation of human recombinant and native 5-HT receptors of enteric neurons</article-title>. <source>Neurogastroenterol Motil</source>. <year>2013</year>;<volume>25</volume>(<issue>5</issue>):<fpage>439</fpage>-<lpage>e302</lpage>.</citation>
</ref>
<ref id="bibr53-0884533613491982">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaptchuk</surname><given-names>TJ</given-names></name>
</person-group>. <article-title>Acupuncture: theory, efficacy, and practice</article-title>. <source>Ann Intern Med</source>. <year>2002</year>;<volume>136</volume>(<issue>5</issue>):<fpage>374</fpage>-<lpage>383</lpage>.</citation>
</ref>
<ref id="bibr54-0884533613491982">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>L</given-names></name>
</person-group>. <article-title>Clinical observation on acupuncture treatment in 35 cases of diabetic gastroparesis</article-title>. <source>J Tradit Chin Med</source>. <year>2004</year>;<volume>24</volume>(<issue>3</issue>):<fpage>163</fpage>-<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr55-0884533613491982">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>CP</given-names></name>
<name><surname>Kao</surname><given-names>CH</given-names></name>
<name><surname>Chen</surname><given-names>WK</given-names></name>
<name><surname>Lo</surname><given-names>WY</given-names></name>
<name><surname>Hsieh</surname><given-names>CL</given-names></name>
</person-group>. <article-title>A single-blinded, randomized pilot study evaluating effects of electroacupuncture in diabetic patients with symptoms suggestive of gastroparesis</article-title>. <source>J Altern Complement Med</source>. <year>2008</year>;<volume>14</volume>(<issue>7</issue>):<fpage>833</fpage>-<lpage>839</lpage>.</citation>
</ref>
<ref id="bibr56-0884533613491982">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>EJ</given-names></name>
<name><surname>Frazier</surname><given-names>SK</given-names></name>
</person-group>. <article-title>The efficacy of acupressure for symptom management: a systematic review</article-title>. <source>J Pain Symptom Manage</source>. <year>2011</year>;<volume>42</volume>(<issue>4</issue>):<fpage>589</fpage>-<lpage>603</lpage>.</citation>
</ref>
<ref id="bibr57-0884533613491982">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rashed</surname><given-names>H</given-names></name>
<name><surname>Cutts</surname><given-names>T</given-names></name>
<name><surname>Abell</surname><given-names>T</given-names></name><etal/>
</person-group>. <article-title>Predictors of response to a behavioral treatment in patients with chronic gastric motility disorders</article-title>. <source>Dig Dis Sci</source>. <year>2002</year>;<volume>47</volume>(<issue>5</issue>):<fpage>1020</fpage>-<lpage>1026</lpage>.</citation>
</ref>
<ref id="bibr58-0884533613491982">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bouras</surname><given-names>EP</given-names></name>
<name><surname>Talley</surname><given-names>NJ</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Effects of amitriptyline on gastric sensorimotor function and postprandial symptoms in healthy individuals: a randomized, double-blind, placebo-controlled trial</article-title>. <source>Am J Gastroenterol</source>. <year>2008</year>;<volume>103</volume>(<issue>8</issue>):<fpage>2043</fpage>-<lpage>2050</lpage>.</citation>
</ref>
<ref id="bibr59-0884533613491982">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prakash</surname><given-names>C</given-names></name>
<name><surname>Lustman</surname><given-names>PJ</given-names></name>
<name><surname>Freedland</surname><given-names>KE</given-names></name>
<name><surname>Clouse</surname><given-names>RE</given-names></name>
</person-group>. <article-title>Tricyclic antidepressants for functional nausea and vomiting: clinical outcome in 37 patients</article-title>. <source>Dig Dis Sci</source>. <year>1998</year>;<volume>43</volume>(<issue>9</issue>):<fpage>1951</fpage>-<lpage>1956</lpage>.</citation>
</ref>
<ref id="bibr60-0884533613491982">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sawhney</surname><given-names>MS</given-names></name>
<name><surname>Prakash</surname><given-names>C</given-names></name>
<name><surname>Lustman</surname><given-names>PJ</given-names></name>
<name><surname>Clouse</surname><given-names>RE</given-names></name>
</person-group>. <article-title>Tricyclic antidepressants for chronic vomiting in diabetic patients</article-title>. <source>Dig Dis Sci</source>. <year>2007</year>;<volume>52</volume>(<issue>2</issue>):<fpage>418</fpage>-<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr61-0884533613491982">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>SW</given-names></name>
<name><surname>Shin</surname><given-names>IS</given-names></name>
<name><surname>Kim</surname><given-names>JM</given-names></name><etal/>
</person-group>. <article-title>Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment</article-title>. <source>Psychosomatics</source>. <year>2006</year>;<volume>47</volume>(<issue>5</issue>):<fpage>440</fpage>-<lpage>442</lpage>.</citation>
</ref>
<ref id="bibr62-0884533613491982">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moshiree</surname><given-names>B</given-names></name>
<name><surname>McDonald</surname><given-names>R</given-names></name>
<name><surname>Hou</surname><given-names>W</given-names></name>
<name><surname>Toskes</surname><given-names>PP</given-names></name>
</person-group>. <article-title>Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis</article-title>. <source>Dig Dis Sci</source>. <year>2010</year>;<volume>55</volume>(<issue>3</issue>):<fpage>675</fpage>-<lpage>683</lpage>.</citation>
</ref>
<ref id="bibr63-0884533613491982">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ray</surname><given-names>WA</given-names></name>
<name><surname>Murray</surname><given-names>KT</given-names></name>
<name><surname>Hall</surname><given-names>K</given-names></name>
<name><surname>Arbogast</surname><given-names>PG</given-names></name>
<name><surname>Stein</surname><given-names>CM</given-names></name>
</person-group>. <article-title>Azithromycin and the risk of cardiovascular death</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>366</volume>(<issue>20</issue>):<fpage>1881</fpage>-<lpage>1890</lpage>.</citation>
</ref>
<ref id="bibr64-0884533613491982">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fontana</surname><given-names>RJ</given-names></name>
<name><surname>Barnett</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review</article-title>. <source>Am J Gastroenterol</source>. <year>1996</year>;<volume>91</volume>(<issue>10</issue>):<fpage>2174</fpage>-<lpage>2178</lpage>.</citation>
</ref>
<ref id="bibr65-0884533613491982">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kao</surname><given-names>I</given-names></name>
<name><surname>Drachman</surname><given-names>DB</given-names></name>
<name><surname>Price</surname><given-names>DL</given-names></name>
</person-group>. <article-title>Botulinum toxin: mechanism of presynaptic blockade</article-title>. <source>Science</source>. <year>1976</year>;<volume>193</volume>(<issue>4259</issue>):<fpage>1256</fpage>-<lpage>1258</lpage>.</citation>
</ref>
<ref id="bibr66-0884533613491982">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhutani</surname><given-names>MS</given-names></name>
</person-group>. <article-title>Gastrointestinal uses of botulinum toxin</article-title>. <source>Am J Gastroenterol</source>. <year>1997</year>;<volume>92</volume>(<issue>6</issue>):<fpage>929</fpage>-<lpage>933</lpage>.</citation>
</ref>
<ref id="bibr67-0884533613491982">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>LS</given-names></name>
<name><surname>Szych</surname><given-names>GA</given-names></name>
<name><surname>Kantor</surname><given-names>SB</given-names></name><etal/>
</person-group>. <article-title>Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle</article-title>. <source>Am J Gastroenterol</source>. <year>2002</year>;<volume>97</volume>(<issue>7</issue>):<fpage>1653</fpage>-<lpage>1660</lpage>.</citation>
</ref>
<ref id="bibr68-0884533613491982">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lacy</surname><given-names>BE</given-names></name>
<name><surname>Zayat</surname><given-names>EN</given-names></name>
<name><surname>Crowell</surname><given-names>MD</given-names></name>
<name><surname>Schuster</surname><given-names>MM</given-names></name>
</person-group>. <article-title>Botulinum toxin for the treatment of gastroparesis: a preliminary report</article-title>. <source>Am J Gastroenterol</source>. <year>2002</year>;<volume>97</volume>(<issue>6</issue>):<fpage>1548</fpage>-<lpage>1552</lpage>.</citation>
</ref>
<ref id="bibr69-0884533613491982">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bromer</surname><given-names>MQ</given-names></name>
<name><surname>Friedenberg</surname><given-names>F</given-names></name>
<name><surname>Miller</surname><given-names>LS</given-names></name>
<name><surname>Fisher</surname><given-names>RS</given-names></name>
<name><surname>Swartz</surname><given-names>K</given-names></name>
<name><surname>Parkman</surname><given-names>HP</given-names></name>
</person-group>. <article-title>Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis</article-title>. <source>Gastrointest Endosc</source>. <year>2005</year>;<volume>61</volume>(<issue>7</issue>):<fpage>833</fpage>-<lpage>839</lpage>.</citation>
</ref>
<ref id="bibr70-0884533613491982">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coleski</surname><given-names>R</given-names></name>
<name><surname>Anderson</surname><given-names>MA</given-names></name>
<name><surname>Hasler</surname><given-names>WL</given-names></name>
</person-group>. <article-title>Factors associated with symptom response to pyloric injection of botulinum toxin in a large series of gastroparesis patients</article-title>. <source>Dig Dis Sci</source>. <year>2009</year>;<volume>54</volume>(<issue>12</issue>):<fpage>2634</fpage>-<lpage>2642</lpage>.</citation>
</ref>
<ref id="bibr71-0884533613491982">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arts</surname><given-names>J</given-names></name>
<name><surname>Holvoet</surname><given-names>L</given-names></name>
<name><surname>Caenepeel</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2007</year>;<volume>26</volume>(<issue>9</issue>):<fpage>1251</fpage>-<lpage>1258</lpage>.</citation>
</ref>
<ref id="bibr72-0884533613491982">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Friedenberg</surname><given-names>FK</given-names></name>
<name><surname>Palit</surname><given-names>A</given-names></name>
<name><surname>Parkman</surname><given-names>HP</given-names></name>
<name><surname>Hanlon</surname><given-names>A</given-names></name>
<name><surname>Nelson</surname><given-names>DB</given-names></name>
</person-group>. <article-title>Botulinum toxin A for the treatment of delayed gastric emptying</article-title>. <source>Am J Gastroenterol</source>. <year>2008</year>;<volume>103</volume>(<issue>2</issue>):<fpage>416</fpage>-<lpage>423</lpage>.</citation>
</ref>
<ref id="bibr73-0884533613491982">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bai</surname><given-names>Y</given-names></name>
<name><surname>Xu</surname><given-names>MJ</given-names></name>
<name><surname>Yang</surname><given-names>X</given-names></name><etal/>
</person-group>. <article-title>A systematic review on intrapyloric botulinum toxin injection for gastroparesis</article-title>. <source>Digestion</source>. <year>2010</year>;<volume>81</volume>(<issue>1</issue>):<fpage>27</fpage>-<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr74-0884533613491982">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname><given-names>Z</given-names></name>
<name><surname>Forster</surname><given-names>J</given-names></name>
<name><surname>Sarosiek</surname><given-names>I</given-names></name>
<name><surname>McCallum</surname><given-names>RW</given-names></name>
</person-group>. <article-title>Treatment of gastroparesis with electrical stimulation</article-title>. <source>Dig Dis Sci</source>. <year>2003</year>;<volume>48</volume>(<issue>5</issue>):<fpage>837</fpage>-<lpage>848</lpage>.</citation>
</ref>
<ref id="bibr75-0884533613491982">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abell</surname><given-names>T</given-names></name>
<name><surname>McCallum</surname><given-names>R</given-names></name>
<name><surname>Hocking</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Gastric electrical stimulation for medically refractory gastroparesis</article-title>. <source>Gastroenterology</source>. <year>2003</year>;<volume>125</volume>(<issue>2</issue>):<fpage>421</fpage>-<lpage>428</lpage>.</citation>
</ref>
<ref id="bibr76-0884533613491982">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abell</surname><given-names>TL</given-names></name>
<name><surname>Van Cutsem</surname><given-names>E</given-names></name>
<name><surname>Abrahamsson</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Gastric electrical stimulation in intractable symptomatic gastroparesis</article-title>. <source>Digestion</source>. <year>2002</year>;<volume>66</volume>(<issue>4</issue>):<fpage>204</fpage>-<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr77-0884533613491982">
<label>77.</label>
<citation citation-type="journal">
<collab>Humanitarian device exception for Enterra device</collab>. <source>Federal Registry</source>. <year>2000</year>;<volume>65</volume>:<fpage>78495</fpage>-<lpage>78496</lpage>.</citation>
</ref>
<ref id="bibr78-0884533613491982">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abell</surname><given-names>T</given-names></name>
<name><surname>Lou</surname><given-names>J</given-names></name>
<name><surname>Tabbaa</surname><given-names>M</given-names></name>
<name><surname>Batista</surname><given-names>O</given-names></name>
<name><surname>Malinowski</surname><given-names>S</given-names></name>
<name><surname>Al-Juburi</surname><given-names>A</given-names></name>
</person-group>. <article-title>Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow-up</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2003</year>;<volume>27</volume>(<issue>4</issue>):<fpage>277</fpage>-<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr79-0884533613491982">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Grady</surname><given-names>G</given-names></name>
<name><surname>Egbuji</surname><given-names>JU</given-names></name>
<name><surname>Du</surname><given-names>P</given-names></name>
<name><surname>Cheng</surname><given-names>LK</given-names></name>
<name><surname>Pullan</surname><given-names>AJ</given-names></name>
<name><surname>Windsor</surname><given-names>JA</given-names></name>
</person-group>. <article-title>High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis</article-title>. <source>World J Surg</source>. <year>2009</year>;<volume>33</volume>(<issue>8</issue>):<fpage>1693</fpage>-<lpage>1701</lpage>.</citation>
</ref>
<ref id="bibr80-0884533613491982">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chu</surname><given-names>H</given-names></name>
<name><surname>Lin</surname><given-names>Z</given-names></name>
<name><surname>Zhong</surname><given-names>L</given-names></name>
<name><surname>McCallum</surname><given-names>RW</given-names></name>
<name><surname>Hou</surname><given-names>X</given-names></name>
</person-group>. <article-title>Treatment of high-frequency gastric electrical stimulation for gastroparesis</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2012</year>;<volume>27</volume>(<issue>6</issue>):<fpage>1017</fpage>-<lpage>1026</lpage>.</citation>
</ref>
<ref id="bibr81-0884533613491982">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abell</surname><given-names>TL</given-names></name>
<name><surname>Johnson</surname><given-names>WD</given-names></name>
<name><surname>Kedar</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>A double-masked, randomized, placebo-controlled trial of temporary endoscopic mucosal gastric electrical stimulation for gastroparesis</article-title>. <source>Gastrointest Endosc</source>. <year>2011</year>;<volume>74</volume>(<issue>3</issue>):<fpage>496</fpage>-<lpage>503</lpage> e3.</citation>
</ref>
<ref id="bibr82-0884533613491982">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>CH</given-names></name>
<name><surname>Nelson</surname><given-names>DK</given-names></name>
</person-group>. <article-title>Venting percutaneous gastrostomy in the treatment of refractory idiopathic gastroparesis</article-title>. <source>Gastrointest Endosc</source>. <year>1998</year>;<volume>47</volume>(<issue>1</issue>):<fpage>67</fpage>-<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr83-0884533613491982">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murr</surname><given-names>MM</given-names></name>
<name><surname>Sarr</surname><given-names>MG</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name>
</person-group>. <article-title>The surgeon’s role in the treatment of chronic intestinal pseudoobstruction</article-title>. <source>Am J Gastroenterol</source>. <year>1995</year>;<volume>90</volume>(<issue>12</issue>):<fpage>2147</fpage>-<lpage>2151</lpage>.</citation>
</ref>
<ref id="bibr84-0884533613491982">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hibbard</surname><given-names>ML</given-names></name>
<name><surname>Dunst</surname><given-names>CM</given-names></name>
<name><surname>Swanstrom</surname><given-names>LL</given-names></name>
</person-group>. <article-title>Laparoscopic and endoscopic pyloroplasty for gastroparesis results in sustained symptom improvement</article-title>. <source>J Gastrointest Surg</source>. <year>2011</year>;<volume>15</volume>(<issue>9</issue>):<fpage>1513</fpage>-<lpage>1519</lpage>.</citation>
</ref>
<ref id="bibr85-0884533613491982">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>MP</given-names></name>
<name><surname>Maganti</surname><given-names>K</given-names></name>
</person-group>. <article-title>A systematic review of surgical therapy for gastroparesis</article-title>. <source>Am J Gastroenterol</source>. <year>2003</year>;<volume>98</volume>(<issue>10</issue>):<fpage>2122</fpage>-<lpage>2129</lpage>.</citation>
</ref>
<ref id="bibr86-0884533613491982">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mathias</surname><given-names>JR</given-names></name>
<name><surname>Fernandez</surname><given-names>A</given-names></name>
<name><surname>Sninsky</surname><given-names>CA</given-names></name>
<name><surname>Clench</surname><given-names>MH</given-names></name>
<name><surname>Davis</surname><given-names>RH</given-names></name>
</person-group>. <article-title>Nausea, vomiting, and abdominal pain after Roux-en-Y anastomosis: motility of the jejunal limb</article-title>. <source>Gastroenterology</source>. <year>1985</year>;<volume>88</volume>(<issue>1 pt 1</issue>):<fpage>101</fpage>-<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr87-0884533613491982">
<label>87.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miedema</surname><given-names>BW</given-names></name>
<name><surname>Kelly</surname><given-names>KA</given-names></name>
<name><surname>Camilleri</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Human gastric and jejunal transit and motility after Roux gastrojejunostomy</article-title>. <source>Gastroenterology</source>. <year>1992</year>;<volume>103</volume>(<issue>4</issue>):<fpage>1133</fpage>-<lpage>1143</lpage>.</citation>
</ref>
<ref id="bibr88-0884533613491982">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van der Mijle</surname><given-names>HC</given-names></name>
<name><surname>Beekhuis</surname><given-names>H</given-names></name>
<name><surname>Bleichrodt</surname><given-names>RP</given-names></name>
<name><surname>Kleibeuker</surname><given-names>JH</given-names></name>
</person-group>. <article-title>Transit disorders of the gastric remnant and Roux limb after Roux-en-Y gastrojejunostomy: relation to symptomatology and vagotomy</article-title>. <source>Br J Surg</source>. <year>1993</year>;<volume>80</volume>(<issue>1</issue>):<fpage>60</fpage>-<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr89-0884533613491982">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tjeerdsma</surname><given-names>HC</given-names></name>
<name><surname>Smout</surname><given-names>AJ</given-names></name>
<name><surname>Akkermans</surname><given-names>LM</given-names></name>
</person-group>. <article-title>Voluntary suppression of defecation delays gastric emptying</article-title>. <source>Dig Dis Sci</source>. <year>1993</year>;<volume>38</volume>(<issue>5</issue>):<fpage>832</fpage>-<lpage>836</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>